IQVIA downgraded by HSBC Securities with a new price target
$IQV
Biotechnology: Commercial Physical & Biological Resarch
Health Care
HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/25/2025 | $160.00 | Buy → Hold | HSBC Securities |
| 4/10/2025 | $170.00 | Overweight → Equal Weight | Barclays |
| 2/3/2025 | Buy → Neutral | BTIG Research | |
| 12/20/2024 | $250.00 | Overweight | Stephens |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 9/4/2024 | $275.00 | Outperform | RBC Capital Mkts |
| 7/24/2024 | $266.00 → $242.00 | Buy → Hold | Jefferies |
| 6/6/2024 | $270.00 | Buy | Goldman |
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced today that the global independent research and analysis firm Everest Group® has named IQVIA a "front-runner generative AI leader" for the life sciences industry in its recent report, "AI-deas to Action: Operationalizing Generative AI in Life Sciences." IQVIA was the only clinical research organization to receive the highest ranking of front-runner in the report, which measures the value impact of end-to-end generative AI capabilities for 15 carefully selected broad-based AI companies, CROs and life sciences specialists and niche firms. IQVIA is also the only
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive
Research and development funding has increased: Biopharma funding increased for the second consecutive year in 2024. Total large-pharma R&D spending continued to increase. Clinical trial start volumes have stabilized: Trial starts have fully returned to pre-pandemic levels. Priorities have continued to shift. Clinical program productivity has increased: Improvement in productivity was driven by a success-rate increase in Phase III trials. Cycle times are stabilizing: Enrollment duration – the largest opportunity to improve trial cycle times – stabilized in 2024 after having increased between 2021 and 2023. Inter-trial intervals now typically account for 17 months
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive
Revenue of $3,958 million for the fourth quarter, $15,405 million for the full year GAAP Net Income of $437 million for the fourth quarter, $1,373 million for the full year Adjusted EBITDA of $996 million for the fourth quarter, $3,684 million for the full year GAAP Diluted Earnings per Share of $2.42 for the fourth quarter, $7.49 for the full year Adjusted Diluted Earnings per Share of $3.12 for the fourth quarter, $11.13 for the full year R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency TAS Revenue of $1,658 million fo
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 6, 2025. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, part
HSBC Securities downgraded IQVIA from Buy to Hold and set a new price target of $160.00
Barclays downgraded IQVIA from Overweight to Equal Weight and set a new price target of $170.00
BTIG Research downgraded IQVIA from Buy to Neutral
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
DEFA14A - IQVIA HOLDINGS INC. (0001478242) (Filer)